Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1258-1262

  Apakama, I ^a   Robinson, M C ^a   Walter, N M ^a   Charlton, R G ^a   Royds, J A ^b   Fuller, C E ^b   Neal, D E ^a   Hamdy, F C ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Apoptosis; bcl 2; Oncogene; p53; Prostate cancer; Tumour suppressor gene

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; GENE EXPRESSION; HORMONE RESISTANCE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0029851180     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.526     Document Type: Article

References (35)

1. AIHARA M, TRUONG LD, DUNN JK, WHEELER TM, SCARDINO PT AND THOMPSON TC. (1994). Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum. Pathol., 25, 797-801.
2. APRIKIAN AG, SARKIS AS, FAIR WR, ZHANG Z-F, FUKS Z AND CORDON-CARDO C. (1994). Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151, 1276 - 1280.
3. BAAS IO, MULDER J-WR, OFFERHAUS JA, VOGELSTEIN B AND HAMILTON SR. (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172, 5-12.
4. BERGES RR, FURUYA Y, REMINGTON L, ENGLISH HF, JACKS T AND ISAACS JT. (1993). Cell proliferation, DNA repair, and p53 function are not required for programmed cell death of prostatic glandular cells induced by androgen ablation. Proc. Natl Acad. Sci. USA, 90, 8910-8914.
5. BISHOP JM. (1991). Molecular themes in carcinogenesis. Cell, 64, 235 - 248.
6. BISSONNETTE RP, ECHEVFRRI F, MAHBOUBI A AND GREEN DR. (1992). Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature, 359, 552-554.
7. BRÄNDSTRÖM A, WESTIN P, BERGH A, CAJANDER S AND DAMBFR J-E. (1994). Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenoscarcinoma in the rat. Cancer Res., 54, 3594-3601.
8. COLOMBEL M, OLSSON CA, NG P-Y AND BUTTYAN R. (1992). Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res., 52, 4313 - 4319.
9. COLOMBEL M, SYMMANS F, GIL S, O'TOOLE KM, CHOPIN D, BENSON M, OLSSON C, KORSMEYER S AND BUTTYAN R. (1993). Detection of apoptosis suppressing oneoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol., 143, 390-400.
10. FISHER CJ, GILLETT CE, VOJTESEK DM, BARNES DM AND MILLIS RR. (1994). Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J. Cancer, 69, 20-31.
11. HALDAR S, NEGRINI M, MONNE M, SABBIONI S AND CROCE CM. (1994). Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54, 2095 - 2097.
12. HALL PA AND LANE DP. (1994). p53 in tumour pathology: can we trust immunohistochemistry? Revisited! J. Pathol., 172, 1-4.
13. HAMDY FC, THURRELL W, LAWRY J, ANDERSON JB, PARSONS MA, REES RC AND ROYDS JA. (1993). p53 mutant expression correlated with hormone sensitivity and prognosis in human prostatic adenocarcinoma. J. Urol., 149, 377A.
14. HOCKENBURY D, NUǸEZ G, MILLIMAN C, SCHREIBER RD AND KORSMEYER SJ. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334-336.
15. HUGGINS C AND HODGES CV. (1941). Studies on prostate cancer: The effect of castration, of oestrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res., 1, 293 - 297.
16. KERR JFR, WINTERFORD CM AND HARMON BV. (1994). Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73, 2013-2026.
17. KORSMEYER SJ. (1992). Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 80, 879 - 886.
18. KYPRIANOU N, ENGLISH HF AND ISAACS JT. (1990). Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50, 3748-3753.
19. LANE DP. (1992). p53, guardian of the genome. Nature, 358, 15-16.
20. LEEK RD, KAKLAMANIS L, PEZZELLA F, GATTER KC AND HARRIS AL. (1994). bcl-2 in normal human breast and carcinoma, associated with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer, 69, 135 - 139.
21. MCDONNELL TJ, TRONCOSO P, BRISBAY SM, LOGOTHETIS C, CHUNG LWK, HSIER J-T, TU S-M AND CAMPBELL ML. (1992). Expression of the protooncogene bcl-2 in prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52, 6940-6944.
22. MARIN MC, HSU B, MEYN RE, DONEHOWER LA, EL-NAGGAR AK AND MCDONNELL TJ. (1994). Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene, 9, 3107-3112.
23. MARSHALL C. (1991). Tumor suppressor genes. Cell, 64, 313-326.
24. MELLON K, THOMPSON S, CHARLTON RG, MARSH C, ROBINSON M, LANE DP, HARRIS AL, HORNE CHW AND NEAL DE. (1992). p53, c-erb and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol., 147, 496-499.
25. MYERS RB, OELSCHLAGER D, SRIVASTAVA S AND GRIZZLE WE. (1994). Accumulation of the p53 protein occurs more frequently in metastatic than localized prostatic adenocarcinomas. The Prostate, 25, 243-248.
26. NAVONE N, TRONCOSO P, PISTERS LL, GOODROW TL, PALMER JL, NICHOLS WW, VON ESCHENBACH AC AND CONTI CJ. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl Cancer Inst., 85, 1657-1699.
27. OFFICE OF POPULATION CENSUSES AND SURVEYS. (1993). Cancer Statistics. Registrations 1987. England and Wales. Series MB1 No.20. HMSO: London.
28. ÖFNER D, RIEHEMANN K, MAIER H, REIDMANN B, NEHODA H, TÖTSCH M, BÖCKER W, JASANI B AND SCHMID KW. (1995). Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer. 72, 981 - 985.
29. PEZZELLA F, TURLEY H, KUZU I, TUNGEKAR MF, DUNNILL MS, PERCE CB, HARRIS A, GATTER K AND MASON D. (1993). Bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329, 690 - 694.
30. PIRIS MA, PEZZELLA F, MARTINEZ-MONTERO JC, ORRADRE J., VILLUENDAS R, SANCHEZ-BEATO M, CUEN AR, CRUZ MA, MARTINEZ B, GARRIDO MC, GATTER K, AIELLO A, DELIA D, GIARDINI R AND RILKE F. (1994). p53 and bcl-2 expression in high grade B-cell lymphomas: correlation with survival time. Br. J. Cancer, 69, 337 - 341.
31. RAFFO AJ, PERLMAN H, CHEN M-W, DAY ML, STREITMAN JS AND BUTTYAN R. (1995). Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55, 4438-4445.
32. SEARLE J, KERR JFR AND BISHOP CJ. (1982). Necrosis and apoptosis: distinct mode of cell death with fundamentally different significance. Pathol. Ann., 17, 229-259.
33. SHAW P, BOVEY R, TARDY S, SAHLI R, SORDAT B AND COSTA J. (1992). Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl Acad. Sci. USA, 89, 4495-4499.
34. VISAKORPI T, KALLIONIEMI O-P, HEIKKINEN A, KOIVULA T AND ISOLA J. (1992). Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumultaion. J. Natl Cancer Inst., 84, 883.
35. WYNFORD-THOMAS D. (1992). p53 in tumour pathology: can we trust immunohistochemistry? J. Pathol., 166, 329-330.